Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on Magellan Midstream, Raises Price Target to $53

Barclays analyst Christine Cho maintains Magellan Midstream (NYSE:MMP) with a Overweight and raises the price target from $50 to $53.
byBenzinga Newsdesk
October 19, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Christine Cho maintains Magellan Midstream (NYSE:MMP) with a Overweight and raises the price target from $50 to $53.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Ascendis Pharma’s VISEN Says Has Received Investigational New Drug Approval From Center For Drug Evaluation Of National Medical Products Administration For Phase 3 China Clinical Trial Of TransCon PTH Solution For Injection

By Benzinga Newsdesk
Today, 3:21 PM
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial 1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center

ASND